Cost-effectiveness of 12-month VenG for CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses a study estimating the cost-effectiveness of a 12-month fixed duration of venetoclax in combination with obinutuzumab (VenG) for the first-line treatment of chronic lymphocytic leukemia (CLL) in the United States. A 12-month fixed-duration treatment with VenG appears to be a cost-effective standard therapy for CLL patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Watch video Cost-effectiveness of 12-month VenG for CLL online without registration, duration hours minute second in high quality. This video was added by user VJHemOnc – Video Journal of Hematology & HemOnc 21 January 2020, don't forget to share it with your friends and acquaintances, it has been viewed on our site 150 once and liked it 0 people.